Preoperative RT plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation & tumor response in node-positive HR+/HER2-negative breast cancer versus pembrolizumab alone, a small randomized trial showed. #SABCS25 @guptalabunc.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
Increased immune activation, clear nodes, pCR with tumor-directed low-dose RT
www.medpagetoday.com
December 15, 2025 at 6:49 PM
Preoperative RT plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation & tumor response in node-positive HR+/HER2-negative breast cancer versus pembrolizumab alone, a small randomized trial showed. #SABCS25 @guptalabunc.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Receiving neoadjuvant endocrine therapy enabled many postmenopausal patients with ER-positive, HER2-negative #breastcancer to undergo breast-conserving surgery, including some who had been considered ineligible for BCS. Presented at @sabcs.bsky.social #SABCS25.
https://bit.ly/3MwMWTW
#bcsm
https://bit.ly/3MwMWTW
#bcsm
December 14, 2025 at 10:52 PM
Receiving neoadjuvant endocrine therapy enabled many postmenopausal patients with ER-positive, HER2-negative #breastcancer to undergo breast-conserving surgery, including some who had been considered ineligible for BCS. Presented at @sabcs.bsky.social #SABCS25.
https://bit.ly/3MwMWTW
#bcsm
https://bit.ly/3MwMWTW
#bcsm
The ADC sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer, a randomized trial showed. #SABCS25 @breastcancerdoc.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial
Blinded review showed same PFS for chemo, sacituzumab govitecan, but local review favored the ADC
www.medpagetoday.com
December 12, 2025 at 8:43 PM
The ADC sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer, a randomized trial showed. #SABCS25 @breastcancerdoc.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Now enrolling! Dr. Dean Shumway of Mayo Clinic leads Alliance A012301 (LoTam) comparing low-dose tamoxifen vs usual hormonal therapy for post-menopausal women with early-stage HER2-negative #breastcancer. Learn more: https://bit.ly/Alliance-A012301 #NCI #NCTN #BCsm #ClinicalTrials
December 12, 2025 at 3:00 PM
Now enrolling! Dr. Dean Shumway of Mayo Clinic leads Alliance A012301 (LoTam) comparing low-dose tamoxifen vs usual hormonal therapy for post-menopausal women with early-stage HER2-negative #breastcancer. Learn more: https://bit.ly/Alliance-A012301 #NCI #NCTN #BCsm #ClinicalTrials
Ismail Ajjawi @yaleschoolofmed.bsky.social ’27 presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
December 12, 2025 at 1:43 AM
Ismail Ajjawi @yaleschoolofmed.bsky.social ’27 presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer @sabcs.bsky.social #SABCS25 #bcsm
www.onclive.com/view/elacest...
www.onclive.com/view/elacest...
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer | OncLive
Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.
www.onclive.com
December 12, 2025 at 12:52 AM
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer @sabcs.bsky.social #SABCS25 #bcsm
www.onclive.com/view/elacest...
www.onclive.com/view/elacest...
How I Protect My Peace While Living With Metastatic Breast Cancer
A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and the HER2 protein, which makes…
A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and the HER2 protein, which makes…
How I Protect My Peace While Living With Metastatic Breast Cancer
A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and the HER2 protein, which makes certain treatments like hormone therapy ineffective). I was 29, so this diagnosis felt shocking—just totally out of left field. I was not worried it was cancer when I first found the lump; the thought didn’t even occur to me.
copyinvisible.com
December 11, 2025 at 3:39 AM
How I Protect My Peace While Living With Metastatic Breast Cancer
A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and the HER2 protein, which makes…
A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and the HER2 protein, which makes…
AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer
->News-Medical | #ai | More from Lil Dr Glen EcoChat at BigEarthData.ai
->News-Medical | #ai | More from Lil Dr Glen EcoChat at BigEarthData.ai
AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12,...
www.news-medical.net
December 11, 2025 at 2:27 AM
AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer
https://www.newsbeep.com/au/340158/
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification…
https://www.newsbeep.com/au/340158/
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification…
AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer - Australia News Beep
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk
www.newsbeep.com
December 10, 2025 at 8:50 PM
AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer
https://www.newsbeep.com/au/340158/
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification…
https://www.newsbeep.com/au/340158/
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification…
New results from the lidERA trial presented at #SABCS2025 show that the oral SERD giredestrant improved invasive disease-free survival for women with early-stage, HR-positive, HER2-negative #breastcancer. 🎧 Listen to Dr. Bardia discuss his research in our latest podcast: https://bit.ly/4rR4Lgy
December 10, 2025 at 7:02 PM
New results from the lidERA trial presented at #SABCS2025 show that the oral SERD giredestrant improved invasive disease-free survival for women with early-stage, HR-positive, HER2-negative #breastcancer. 🎧 Listen to Dr. Bardia discuss his research in our latest podcast: https://bit.ly/4rR4Lgy
(Cont.) ...with hormone receptor (HR)-positive, HER2-negative metastatic #breastcancer, has shown mixed results. In the study sacituzumab govitecan-hziy did not appear to work better than chemotherapy in terms of slowing disease progression — the main objective of the trial.
December 10, 2025 at 5:37 PM
(Cont.) ...with hormone receptor (HR)-positive, HER2-negative metastatic #breastcancer, has shown mixed results. In the study sacituzumab govitecan-hziy did not appear to work better than chemotherapy in terms of slowing disease progression — the main objective of the trial.
HR-positive HER2-negative Breast Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Regor Therapeutics, S
HR-positive HER2-negative Breast Cancer Clinical And Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, And Pipeline Analysis | Regor Therapeutics, S | PressReleaseCC
DelveInsight analyzes that the HR-positive HER2-negative Breast Cancer pipeline includes over 50 leading companies actively developing more than 53 therapies
www.pressreleasecc.com
December 10, 2025 at 10:45 AM
HR-positive HER2-negative Breast Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Regor Therapeutics, S
Trial Tuesday! Haeseong Park MD Dana-Farber Cancer Institute leads Alliance A022102 studying mFOLFIRINOX versus mFOLFOX with or without immunotherapy drug nivolumab for metastatic HER2 negative esophageal, gastroesophageal junction and gastric cancer. Learn more: https://bit.ly/Alliance-A022102
December 9, 2025 at 4:00 PM
Trial Tuesday! Haeseong Park MD Dana-Farber Cancer Institute leads Alliance A022102 studying mFOLFIRINOX versus mFOLFOX with or without immunotherapy drug nivolumab for metastatic HER2 negative esophageal, gastroesophageal junction and gastric cancer. Learn more: https://bit.ly/Alliance-A022102
I know HER2-Negative is a medical thing but it sounds like a caveman talking about why I'm being a bitch.
December 7, 2025 at 4:55 AM
I know HER2-Negative is a medical thing but it sounds like a caveman talking about why I'm being a bitch.
Alterations in the AKT pathway are common in cancer, with the AKT1 E17K mutation found in ~5% of HR+/HER2-negative breast cancers. Our drug, ALTA2618, is designed to selectively target AKT1 E17K, while sparing other AKT isoforms to enhance tolerability without compromising efficacy.
December 4, 2025 at 2:00 PM
Alterations in the AKT pathway are common in cancer, with the AKT1 E17K mutation found in ~5% of HR+/HER2-negative breast cancers. Our drug, ALTA2618, is designed to selectively target AKT1 E17K, while sparing other AKT isoforms to enhance tolerability without compromising efficacy.
HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies And Breakthrough Therapies Shaping The Future Landscape | PressReleaseCC
DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 53+ pipeline
www.pressreleasecc.com
November 29, 2025 at 2:12 AM
HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic #BreastCancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. www.thelancet.com/journals/lan...
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, rando...
Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically
significant improvements in progression-free survival compared with chemotherapy in
patients with HER2-negati...
www.thelancet.com
November 28, 2025 at 10:51 AM
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic #BreastCancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. www.thelancet.com/journals/lan...
"Research, primarily in laboratory and animal studies, has shown that honey bee venom and its main active component, a peptide called melittin, can effectively destroy breast cancer cells, particularly aggressive types like triple-negative and HER2-enriched breast cancer."
November 27, 2025 at 8:08 PM
"Research, primarily in laboratory and animal studies, has shown that honey bee venom and its main active component, a peptide called melittin, can effectively destroy breast cancer cells, particularly aggressive types like triple-negative and HER2-enriched breast cancer."
ER-low/HER2-negative breast cancers demonstrate BRCA1/2 mutation prevalence and features comparable to TNBC
#breastcancer #oncology
pubmed.ncbi.nlm.nih.gov/41238982/?ut...
#breastcancer #oncology
pubmed.ncbi.nlm.nih.gov/41238982/?ut...
Germline BRCA1/2 Mutation Prevalence in Unselected ER-Low/HER2-Negative Breast Cancer - PubMed
ER-low/HER2-negative breast cancers demonstrate BRCA1/2 mutation prevalence and features comparable to TNBC. Applying testing criteria based solely on ER expression may underdiagnose mutation carriers. These findings support expanding BRCA1/2 testing eligibility to include ER-low/HER2-negative tumor …
pubmed.ncbi.nlm.nih.gov
November 24, 2025 at 11:13 AM
ER-low/HER2-negative breast cancers demonstrate BRCA1/2 mutation prevalence and features comparable to TNBC
#breastcancer #oncology
pubmed.ncbi.nlm.nih.gov/41238982/?ut...
#breastcancer #oncology
pubmed.ncbi.nlm.nih.gov/41238982/?ut...
Nou article a #Docusalut: 🦠👩⚕️Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer http://hdl.handle.net/20.500.13003/25869 @idisba.bsky.social #PublicaSalutIB
November 21, 2025 at 8:30 AM
Nou article a #Docusalut: 🦠👩⚕️Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer http://hdl.handle.net/20.500.13003/25869 @idisba.bsky.social #PublicaSalutIB
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
November 18, 2025 at 5:02 PM
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
Nou article a #Docusalut: 🦠Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer http://hdl.handle.net/20.500.13003/25731 @idisba.bsky.social #PublicaSalutIB
November 13, 2025 at 11:01 AM
Nou article a #Docusalut: 🦠Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer http://hdl.handle.net/20.500.13003/25731 @idisba.bsky.social #PublicaSalutIB
#KisqaliAndFemara combination treats HR-positive, HER2-negative breast cancer. Kisqali blocks cancer cell growth; Femara reduces estrogen. More effective together than Femara alone. Used for high-risk early-stage or advanced/metastatic disease with aromatase inhibitors.
What are the benefits of taking Kisqali and Femara together?
Official answer: Taking Kisqali and Femara together can benefit patients with specific types of breast cancer because the medications...
www.drugs.com
November 12, 2025 at 5:25 PM
#KisqaliAndFemara combination treats HR-positive, HER2-negative breast cancer. Kisqali blocks cancer cell growth; Femara reduces estrogen. More effective together than Femara alone. Used for high-risk early-stage or advanced/metastatic disease with aromatase inhibitors.
Stordal: types of breast cancer cont.
breast cancers that don't have hormone recepters or HER2 are Triple Negative. When detected hearly and treated, 85% sruved >= 5 years
breast cancers that don't have hormone recepters or HER2 are Triple Negative. When detected hearly and treated, 85% sruved >= 5 years
November 12, 2025 at 4:22 PM
Stordal: types of breast cancer cont.
breast cancers that don't have hormone recepters or HER2 are Triple Negative. When detected hearly and treated, 85% sruved >= 5 years
breast cancers that don't have hormone recepters or HER2 are Triple Negative. When detected hearly and treated, 85% sruved >= 5 years
#ENVISION SUMMIT SOLTI 2025 Great talk of Dr Timothy Yap from MDACC about new treatmenta for HR+ HER2 negative #breaatcancer patiens. Great expectations! #SOLTI
November 7, 2025 at 10:19 AM
#ENVISION SUMMIT SOLTI 2025 Great talk of Dr Timothy Yap from MDACC about new treatmenta for HR+ HER2 negative #breaatcancer patiens. Great expectations! #SOLTI